CurrentAetnaPolicy 0641

Adoptive Immunotherapy and Cellular Therapy

Defines Aetna's coverage stance on adoptive immunotherapy and cellular therapy, listing specific therapies and many indications considered experimental/investigational; applies to Aetna members nationally unless otherwise specified.

Policy Summary

PayerAetna

PolicyAdoptive Immunotherapy and Cellular Therapy

Policy CodePolicy 0641

Change TypeNo material change

Effective DateAug 20, 2002

Next Review DateJul 11, 2024

Key ActionObtain and submit clinical trial evidence or peer-reviewed outcomes to support prior authorization requests for investigational adoptive or cellular therapies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

ManyIndications experimental

MultipleCodes listed

≈50%Reported response rate

09/13/2023Last review

Coverage Criteria — Experimental / Investigational Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Experimental/investigational coverage exclusions

Aetna considers the following adoptive immunotherapy and cellular therapies experimental and investigational because effectiveness has not been established.

Adoptive immunotherapy (TIL/LAK): Adoptive immunotherapy using tumor-infiltrating lymphocytes (TILs) or lymphokine-activated killer (LAK) cells activated in vitro with interleukin-2 (IL-2) for the listed indications (including Alzheimer disease and other amyloid disorders; esophageal cancer; glioblastoma multiforme; gynecologic cancers; head and neck cancer including nasopharyngeal carcinoma; hepato-cellular carcinoma; intractable viral and other infectious diseases; lung cancer including non-small cell lung cancer; malignant glioma; melanoma; multiple myeloma; medulloblastoma; neuroblastoma; pancreatic cancer; renal cell carcinoma; sporadic inclusion-body myositis; and other malignancies) is considered experimental/investigational due to lack of adequate evidence that it is more beneficial than IL-2 alone.

List is not all-inclusive.

Cellular therapy (broad): Cellular therapy — including cell therapy, embryonic cell therapy, fresh cell therapy, glandular therapy, live cell therapy, organotherapy, MAGE-A4 cell therapy, immune cell therapy, and xenotransplant therapy — for the listed indications (including AIDS/HIV, acute lymphocytic leukemia, angina, arthritis, asthma, azoospermia, broncho-pulmonary dysplasia, cancer, chronic fatigue, chronic kidney disease, colonic diverticulum, COVID-19, diabetes, heart failure, Huntington’s disease, hypertension, ischemic heart disease and cardiomyopathies, ischemic stroke, minimization of general immunosuppression in kidney transplant recipients, motor neuron diseases such as ALS, musculoskeletal disorders, myocardial infarction, non-ischemic cardiomyopathy, orthopedic disorders, osteoarthritis and focal cartilage defects, peripheral arterial disease/critical limb ischemia, tendinopathy, traumatic brain injury, and other listed conditions) is considered experimental/investigational due to lack of adequate evidence.

List is not all-inclusive.

CAR T for solid tumors: Chimeric antigen receptor (CAR) T-cell therapy (examples: axicabtagene ciloleucel [Yescarta], brexucabtagene autoleucel [Tecartus], ciltacabtagene autoleucel [Carvykti], idecabtagene vicleucel [Abecma], lisocabtagene maraleucel [Breyanzi], tisagenlecleucel [Kymriah]) for the treatment of solid tumors is considered experimental/investigational.

See related CAR T policies for product-specific guidance.

Evidence summary (informational)

Evidence summary and observed findings in selected studies (informational):

Head and Neck cancers - small studies: Phase II and small studies reported objective tumor regression and tissue immune responses after ex-vivo expanded Vα24 NKT cells and αGalCer-pulsed APCs in locally recurrent HNSCC; sample size was 10 patients with five achieving objective tumor regression and increased NKT cells in tumor tissue associated with regression.

See Yamasaki et al (2011).

EBV-associated nasopharyngeal carcinoma: In a phase I/II trial of EBV-stimulated cytotoxic T-lymphocyte (EBV-CTL) immunotherapy for recurrent/metastatic EBV-associated NPC, 28 patients were enrolled and 21 treated; one complete response was observed, median PFS was 2.2 months and median OS was 16.7 months; investigators concluded durable responses can occur but overall outcomes remain limited and further research is needed.

Investigational therapy was given only after progression on interim chemotherapy.

Breast cancer - DC/CIK + chemotherapy: A meta-analysis of 11 studies reported that dendritic cell (DC)/CIK plus chemotherapy improved complete response (CR), partial response (PR), and overall response rate (ORR) versus chemotherapy alone with no difference in common toxicities; authors cautioned about unstable factors and heterogeneity across studies.

Hu et al (2017).

Melanoma - TIL and combinations: A non-randomized study in stage III malignant melanoma reported that adjuvant TIL plus IFN-α was associated with significantly improved disease-free survival and overall survival versus IFN-α alone; authors recommended multicenter randomized trials to confirm benefit.

Li et al (2017).

Gynecologic cancers - ACT: Systematic review/meta-analysis (401 patients; 238 with gynecologic cancers) reported ORR 26.3% and disease control rate 57.6%; TIL therapy and lymphodepletion were associated with higher responses, but the rate of grade 3–4 toxicity was 46.0%.

Son et al (2022).

Unproven animal-derived cell therapies: Cellular therapies involving processed animal organs, embryos, or fetal tissues (fresh cell therapy, live cell therapy, glandular therapy, xenotransplant therapy) lack scientific support and have been strongly advised against by the American Cancer Society due to potential for serious adverse reactions.

Barrett (2008).

Cardiac and vascular cell therapies: Meta-analyses in myocardial infarction, ischemic cardiomyopathy, and critical limb ischemia show mixed results: peri-procedural adverse events clustered with intra-coronary delivery and G-CSF mobilization; some pooled analyses report improvements in infarct size, perfusion, pain scores and surrogate measures, but placebo-controlled RCTs often showed reduced or non-significant effects, indicating need for larger placebo-controlled trials.

Alvarez et al (2013); Teraa et al (2013); Wang et al (2018).

Evidence limitations and heterogeneity: Authors frequently noted study heterogeneity, small/early-phase trials, variable manufacturing/dosing/regimens, regional trial populations, and short follow-up, limiting generalizability and supporting caution in interpreting reported benefits.

Multiple background reviews and meta-analyses cited these limitations.

Background evidence (informational)

Evidence summaries and consensus findings (no explicit coverage criteria provided in these background excerpts).

Angina and myocardial indications: Meta-analyses of RCTs in refractory angina and STEMI reported improvements in indices of angina, myocardial perfusion, and some clinical outcomes in cell-treated patients but emphasized that trials were small (phase I/II), follow-up short, and that larger phase III randomized trials are needed to determine clinical benefit.

Khan et al (2016); Wang et al (2018).

COVID-19 evidence synthesis: A systematic review and network meta-analysis examined safety and effectiveness of antibody therapies and blood products for COVID-19 using WHO and multiple databases; certainty of evidence assessed with GRADE and analyses were restricted to interventions with sufficient patient/events.

Siemieniuk et al (2021).

Multiple myeloma consensus: ASTCT expert panel used a RAND-modified Delphi to produce 20 consensus statements endorsing auto-HCT consolidation as standard-of-care in newly diagnosed MM, recommending CAR-T in relapsed/refractory MM after ≥4 prior lines, and advising that allo-HCT and frontline CAR-T be used only in clinical trials.

Dhakal et al (2022).

Evidence summaries / expert consensus

Azoospermia evidence summary: Systematic review and meta-analysis of stem cell transplantation for azoospermia in animal models (18 studies) found improved expression of meiosis-related genes (Vasa, Scp3, Dazl) and histologic evidence of spermatogenesis; effects varied by transplant mode, injection site, stem cell type, and species, with xenotransplant and umbilical cord mesenchymal stem cells showing pronounced effects.

Qiu et al (2023).

Multiple myeloma expert recommendations: ASTCT consensus (RAND-modified Delphi) produced 20 statements endorsing auto-HCT consolidation as SOC in newly diagnosed MM, recommending CAR-T in RRMM after ≥4 prior lines, recommending auto-HCT at first relapse for patients not receiving it upfront, and advising lenalidomide maintenance for standard-risk patients; allo-HCT and front-line CAR-T were not recommended outside clinical trials.

Dhakal et al (2022).

This policy lists adoptive immunotherapy and cellular therapies that Aetna considers experimental and investigational because effectiveness has not been established. Note: this policy does not apply to lifileucel for the treatment of advanced melanoma (lifileucel is explicitly excluded from the policy scope).

Available studies and meta-analyses are heterogeneous with respect to patient populations, manufacturing and dosing strategies, combination regimens, and follow-up duration. Review authors have highlighted variability in cytokine type, number of infusion cycles, preparative regimens, and short or inconsistent follow-up, and have cautioned that many positive findings (often from Asian-dominated trials) may not generalize to other settings; randomized trials with adequate follow-up are needed to confirm benefit.

“Cellular therapy” techniques that inject or administer processed animal organ, embryo, or fetal tissues (often called fresh cell therapy, live cell therapy, glandular therapy, xenotransplant therapy) are described as unregulated and unsupported by scientific evidence. National organizations (e.g., the American Cancer Society and CMS) characterize these animal- or embryo-derived products as potentially dangerous and not reasonable and necessary, supporting a noncoverage stance for such unproven xenotransplant/embryonic-derived therapies.

The document summarizes early-phase and dose-escalation trial reports (for example, phase I CAR T studies) that establish feasibility, dosing ranges, and toxicity profiles but reflect small cohorts, variable regimens, and limited intent-to-treat outcome data. The extracted background does not present explicit routine-coverage approvals for these early-phase interventions; instead it reports preliminary efficacy and safety observations and emphasizes the need for further controlled evidence.

Several clinical areas are characterized as experimental or supported only by early-phase data. Examples include bronchopulmonary dysplasia (BPD) where stem/progenitor approaches remain investigational and early clinical trials are ongoing; motor neuron diseases such as ALS/MND where systematic reviews found no eligible RCTs and concluded there is a lack of high-quality evidence; and intra-articular cellular injections for osteoarthritis or focal cartilage defects where trials are heterogeneous and of limited quality. Musculoskeletal cellular therapy trials are increasing but most are phase I/II and incomplete, underscoring limited evidence for routine use across these indications.

The ASTCT expert panel produced consensus recommendations on sequencing of transplantation and cellular therapies in multiple myeloma. The panel endorsed autologous HCT as standard consolidation for newly diagnosed MM and recommended CAR T-cell therapy in relapsed/refractory MM after >= 4 prior lines of therapy. Importantly, the panel advised that frontline allogeneic HCT and frontline CAR-T should only be performed within clinical trials (i.e., not recommended as routine frontline therapy).

Unregulated animal-derived cellular products lack credible evidence of efficacy and have been associated with serious adverse reactions in historical reports. Because these products are described as potentially dangerous and unsupported by scientific data, the document supports treating such therapies as not reasonable and necessary and subject to denial.

Pooled trial data for cartilage injury and related orthopedic outcomes did not demonstrate a clear advantage for stem cell treatment versus other interventions. Although some outcome scales showed improvement in select measures, overall pooled analyses found no consistent superiority of stem cells over comparator treatments, indicating insufficient evidence of net clinical benefit for routine use in cartilage repair.

Systematic reviews and evidence summaries conclude there is a lack of high-quality evidence to guide clinical practice in areas such as ALS/MND and many musculoskeletal/cartilage disorders. The reports emphasize the need for large, prospective randomized controlled trials to determine optimal cell source, dose, route, and patient selection before these interventions can be recommended for routine care.

Billing and Coding

Codes referenced in policy (some noted as not covered for listed indications)mixed

36511	Therapeutic apheresis; for white blood cells.
86357	Natural killer (NK) cells, total count.
88230	Tissue culture for non-neoplastic disorders; lymphocyte.
88237	Tissue culture for neoplastic disorders; bone marrow, blood cells.
88239	solid tumor.
S2107	Adoptive immunotherapy i.e., development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment.
M0075	Cellular therapy.

ICD-10 ranges/examples listed as not covered for indications in the CPBICD-10Not Covered

A00.0 - B99.9	Certain infectious and parasitic diseases.
C00.0 - D09.9	Malignant neoplasms and malignant carcinoid tumors.
E85.0 - E85.9	Amyloidosis.
G30.0 - G30.9	Alzheimer disease.
G72.41	Inclusion body myositis [IBM].
B20	Human immunodeficiency virus [HIV] disease.
E08.0 - E13.9	Diabetes mellitus.
G10	Huntington's disease.
I50.1 - I50.9	Heart failure.
J45.20 - J45.99	Asthma.

1–10 of 11

1/2

No codes listed in this document sectionmixed

No codes listed

Prior lines of therapy for CAR-T in RRMM

ASTCT recommendationCAR‑T is recommended for relapsed/refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy

Threshold value>= 4 prior lines of therapy

Context of recommendationPanel endorsed auto‑HCT as SOC in newly diagnosed MM and recommended CAR‑T for RRMM after prior lines as above; frontline CAR‑T/allo‑HCT only in trials

Provider Actions — Prior Authorization, Documentation, and Denial Risk

Prior Authorization

Prior authorization and affected codes

Prior Authorization Required: Certain adoptive immunotherapy and cellular therapy services and related procedures may require prior authorization. When requesting authorization, include the specific CPT/HCPCS/ICD-10 codes and map each code to the documented indication.

Affected codes (examples from policy): CPT 36511 (therapeutic apheresis; for white blood cells), 86357 (NK cells, total count), 88230/88237/88239 (tissue culture codes), HCPCS S2107 (adoptive immunotherapy per course), HCPCS M0075 (cellular therapy). Lifileucel: no specific permanent code listed; check current coding updates.
Prior authorization requests should reference the documented indication and the exact code(s) submitted for payment.

Prior Authorization

Evidence submission for prior authorization

Evidence required to support prior authorization decisions: submit peer‑reviewed clinical trial reports or registries showing outcomes for the specific tumor type/indication proposed, including patient selection consistent with trial populations. For therapies with limited or mixed evidence, include randomized trial data when available, or robust nonrandomized/registry evidence with defined endpoints.

For CAR T and transplant-related cellular therapies, provide trial population characteristics (refractory status, prior lines of therapy), key efficacy outcomes (OS, PFS/DFS, response rates), and safety data.
When proposing use outside of trial populations, provide convincing peer-reviewed evidence or documented rationale linking expected benefit to the member's clinical scenario.

Documentation Required

Document route and mobilization (informational)

Document route of administration and mobilization methods as informational elements for the review team. Note peri‑procedural adverse events and mobilization agents used (e.g., granulocyte colony‑stimulating factor [G-CSF]) because these affect expected risks and monitoring.

Specify route (intravenous, intra-coronary, trans-endocardial, trans-epicardial, intratesticular, etc.).
Document use of mobilization (e.g., G-CSF) and any associated adverse events documented in the record or anticipated based on published trials.

Prior Authorization

Prior authorization for CAR T and transplant cell therapies

Prior authorization for CAR T-cell and transplant-related cell therapies should verify that the member meets eligibility consistent with pivotal trials or ASTCT consensus recommendations and that sequencing of standard therapies has been considered.

Provide documentation of prior lines of therapy (e.g., chemotherapy, autologous HCT) and refractory/relapsed status as applicable.
For multiple myeloma, reference ASTCT sequencing: auto‑HCT remains standard for newly diagnosed MM; CAR‑T is recommended in RRMM after typically ≥4 prior lines per consensus statements — include documentation of prior therapies.
Include conditioning regimen, planned CAR T product, dosing plan, and supportive care arrangements (e.g., CRS management).

Note

Prior authorization guidance

Prior authorization guidance and operational notes: Clinical Policy Bulletins (CPBs) assist in administering plan benefits but do not guarantee coverage. Actual coverage is governed by the member’s plan documents. Providers are responsible for medical decision-making and must supply complete clinical and product documentation to support medical necessity determinations.

CPBs are descriptive and not contractual; confirming benefits with the member’s plan is recommended.
Include treating provider contact and facility capabilities (e.g., ICU support) when high‑risk therapies are proposed.

Denial Risk

Experimental/investigational denials

Experimental / Investigational and Not Covered: The policy lists multiple adoptive immunotherapy and cellular therapy indications and products considered experimental and investigational due to insufficient evidence. Such uses are at high risk for denial in the absence of compelling, peer‑reviewed evidence.

Examples of noncovered / experimental applications include LAK/TIL + IL‑2 for many listed solid tumors where benefits over IL‑2 alone are unproven.
Unproven cellular therapy modalities include embryonic‑derived cell therapy, xenotransplantation, and many 'fresh cell' or organotherapy practices — these are considered not reasonable and necessary and carry documented safety concerns.

Documentation Required

Evidence limitations affecting coverage

Evidence limitations that may affect coverage decisions: heterogeneity in methods, variable dosing/regimens, short follow‑up, population differences, and small nonrandomized studies can limit interpretability of outcomes. Highlight these limitations in submissions and provide longer follow‑up or randomized data where available.

If relying on meta‑analyses, note heterogeneity (different cytokines, infusion cycles, surveillance methods) and population differences (e.g., Asian‑dominated trials) that may limit external validity.
For cardiac and other non‑oncologic indications, submit systematic review evidence and clear endpoints (e.g., LVEF, mortality) with standardized follow‑up intervals.

Denial Risk

Unproven xenotransplant/embryonic‑derived cell therapies

Unproven xenotransplant and embryonic‑derived cell therapies pose known safety risks and lack evidence of efficacy; these are generally not covered. Documentation proposing such therapies must include high‑quality clinical trial evidence and regulatory oversight to be considered.

Xenotransplantation demonstrated enhanced effects in some animal models (e.g., azoospermia xenotransplant subgroups) but lacks human efficacy/safety data — human use is considered unproven.
Embryonic/fetal tissue–derived cell injections (commercial 'cell therapy' practices) are not supported by scientific evidence and have documented serious adverse reactions; expect denial absent rigorous trial context.

Documentation Required

Safety and rejection endpoints in transplant cell‑therapy trials

Safety and rejection endpoints in transplant cell‑therapy trials should be documented: provide biopsy‑confirmed acute rejection (BCAR) outcomes, infection rates, and centralized AE coding when applicable. These safety endpoints are important for evaluation of immunomodulatory CBMPs in transplant recipients.

Report BCAR incidence and timing (e.g., within 60 weeks), infectious complication rates, and any episodes of immunologic failure.
Include AE coding and adjudication method if available; note whether trials were randomized or single‑arm as this affects interpretability.

Note

No explicit authorization or coverage action

No explicit authorization or coverage action items are specified for every therapy in the background sections; absence of explicit prior authorization language in a background excerpt does not imply coverage. Use plan contract and CPB coding guidance to determine authorization requirements.

When the CPB is silent on a procedure code, verify coverage with the plan and submit clinical justification for review.
ASTCT and systematic review summaries provide context but do not replace plan‑specific authorization rules.

Note

No explicit authorization or denial criteria specified

No explicit authorization or denial criteria are specified in some policy excerpts; operational reviewers will base determinations on clinical evidence, plan terms, and submitted documentation. Ensure submission of complete clinical records and justify deviations from trial populations.

If a requested use lacks explicit CPB criteria, provide detailed justification linking patient factors to available evidence and guidelines.
Include prior treatment chronology and measurable disease status when relevant.

Note

Clinical Policy Bulletins do not constitute coverage offers

Clinical Policy Bulletins are descriptive tools and do not constitute offers of coverage or medical advice. Providers remain responsible for medical decision‑making; plan documents govern actual member benefits.

Confirm member benefits with the plan; CPBs may be updated and are subject to change.
Treating providers are solely responsible for medical advice and treatment decisions.

Billing Rule

Coding and indication documentation

Coding and indication documentation: when submitting for prior authorization and billing, include the CPT/HCPCS/ICD‑10 codes and map each to the documented medical indication. Use the policy’s code lists as a reference and confirm current code validity.

Provide both procedure codes and diagnosis codes that match the member’s documented condition.
If a therapy has no permanent code (e.g., lifileucel historically), describe the product and use the most current temporary or miscellaneous coding and include supporting documentation.

Documentation Required

Required clinical and product documentation

Required clinical and product documentation to include with requests: cellular product type and source, manufacturing details, dosing, lot/batch identifiers, indication, disease stage, prior therapies, and rationale for use. For investigational uses, include informed consent and trial documentation when applicable.

Supply manufacturing and release testing summaries, potency assays, and persistence/engraftment assay results when available.
Document prior standard‑of‑care therapies and sequencing (e.g., prior chemotherapy, HCT) and why the cellular therapy is considered appropriate now.

Documentation Required

CAR T trial documentation elements

CAR T trial documentation elements that inform authorization: include dosing levels, maximum tolerated dose (MTD) if defined, cohort dose escalation details, and adverse event profiles (e.g., cytokine release syndrome [CRS] rates and severity).

Provide feasibility metrics (e.g., percent of patients successfully infused), description of lymphodepletion regimen, observed MTD and dose‑limiting toxicities, and rates of grade ≥3 CRS or neurotoxicity.
Include plans for CRS management, tocilizumab availability, ICU support, and monitoring protocols.

Documentation Required

Clinical evidence documentation

Clinical evidence documentation: for TCR‑ or TIL‑based therapies, include assays showing detection, persistence, and antigen‑specific activity of transferred cells when available, and correlate these laboratory findings with clinical outcomes.

Submit tetramer assays, persistence timepoints, peripheral blood monitoring results, and ex‑vivo functional assays if available.
When persistence is observed without clinical response, provide discussion of potential mechanistic explanations and prior lymphodepletion status.

Note

Summaries of systematic reviews and ASTCT guidance

Summaries of systematic reviews and professional consensus (e.g., ASTCT) may guide sequencing and appropriateness but do not replace case‑level evidence. Include relevant guideline statements and consensus recommendations in the submission to support rationale for therapy timing.

For multiple myeloma, include ASTCT consensus statements on sequencing of auto‑HCT, allo‑HCT, and CAR‑T in NDMM and RRMM when pertinent.
When systematic reviews show modest benefits (e.g., post‑operative NSCLC or HCC adjuvant AIT), provide population and heterogeneity details to support application to the member.

Note

Providers are responsible for medical advice

Provider responsibility disclaimer: Treating providers are solely responsible for medical advice and treatment; administrative policy guidance is not a substitute for individualized clinical judgment.

Ensure clinical rationale and risks are communicated to the member and documented in the record.
Coordinate with the plan for prior authorization and clarify facility capabilities for delivering high‑risk cellular therapies.

Step Therapy

Therapy sequencing evidence and stepwise treatment context

Therapy sequencing evidence and stepwise treatment context: document that standard‑of‑care options were considered or tried before proposing experimental cellular therapy when applicable. Trials often administered investigational therapy after progression on interim chemotherapy or after defined prior lines of therapy.

For recurrent/metastatic nasopharyngeal carcinoma trials, investigational EBV‑CTL was given after progression on interim chemotherapy; document prior chemotherapies and responses.
For glioblastoma and other solid tumors, include prior surgery, radiotherapy, and systemic therapy records to establish sequencing rationale.

Step Therapy

Prior standard chemotherapy before investigational immunotherapy; stepwise management

Prior standard chemotherapy and stepwise management: when investigational immunotherapy is proposed, show documentation of prior standard chemotherapy regimens (including dates and responses) and any optimization of comorbid conditions (e.g., heart failure) before considering cell therapy.

For heart‑failure cell therapy proposals, document optimization of guideline‑directed medical therapy and rationale for experimental therapy.
For oncology indications, supply chronology of prior systemic regimens, radiation, and surgeries to demonstrate appropriate sequencing.

Background and Clinical Context

Adoptive immunotherapy encompasses approaches that harvest lymphocytes from a patient (or donor), activate or expand them ex vivo (for example, lymphokine-activated killer [LAK] cells or tumor-infiltrating lymphocytes [TILs]) often using interleukin‑2, and then reinfuse the cells to mediate anti-tumor effects. The general process involves cell collection, ex‑vivo activation/expansion, and reinfusion following any preparative or lymphodepleting regimens; clinical trials have generally not shown consistent added benefit for LAK/TIL plus IL‑2 over IL‑2 alone.

inv-02 (background overlap): Evidence summary cross-reference for background clinical trial excerpts

Cross-reference: selected background clinical trial excerpts and meta-analytic findings summarized for context (informational overlap with other background sections).

Head & neck and NPC trials: Small clinical studies and early-phase trials in head and neck cancers (including ex-vivo expanded NKT cells with αGalCer-pulsed APCs and EBV-CTL in NPC) reported immune responses and occasional durable responses but overall limited median PFS/OS and need for further research.

Yamasaki et al (2011); Huang et al (2017).

Breast cancer DC/CIK meta-analysis: Meta-analysis of 11 studies found improved CR, PR, and ORR with DC/CIK plus chemotherapy versus chemotherapy alone, with no difference in common toxicities, but authors noted study heterogeneity and need for confirmatory studies.

Hu et al (2017).

Melanoma TIL outcomes: Non-randomized cohort data suggested improved DFS and OS with TIL plus IFN-α versus IFN-α alone in stage III melanoma, but authors recommended multicenter randomized trials to determine true benefit.

Li et al (2017).

Gynecologic ACT synthesis: Systematic review/meta-analysis of ACT in gynecologic cancers reported ORR 26.3% and a high rate of grade 3–4 toxicity (46%), with better responses associated with TIL and lymphodepletion.

Son et al (2022).

Unproven animal-derived therapies caution: Descriptions of cellular therapies derived from animal organs/embryos emphasize lack of efficacy evidence and potential for serious adverse reactions, with ACS advising against their use.

Barrett (2008).

Cardiac cell therapy peri-procedural AEs: Meta-analyses in MI and iCMP identified peri-procedural adverse events concentrated with intra-coronary delivery and G-CSF mobilization; some pooled analyses reported improvements in surrogate measures but emphasized need for larger RCTs.

Alvarez et al (2013); Wang et al (2018).

Critical limb ischemia RCT findings: Meta-analysis of BM-derived cell therapy in critical limb ischemia showed beneficial effects on pain and surrogate measures and reduced amputation in pooled trials, but placebo-controlled RCTs showed reduced and non-significant benefit, underscoring importance of placebo controls.

Teraa et al (2013).

inv-03 (background overlap): Additional background evidence and consensus excerpts

Additional background evidence and consensus excerpts (informational overlap with other background sections):

Angina cardiac outcomes summary: Meta-analysis in refractory angina indicated improvements in anginal episodes, use of anti-anginal medications, CCS class, exercise tolerance, myocardial perfusion, and reduced major adverse cardiac events in cell-treated patients, but investigators called for larger phase III RCTs.

Khan et al (2016).

STEMI BMMNC findings: Meta-analysis of 24 trials (1,536 patients) of bone marrow mononuclear cell therapy after STEMI reported reduced infarct size and improved myocardial perfusion but no significant differences in some wall-motion indices; authors concluded intracoronary BMMNC infusion was safe and recommended further multicenter randomized trials.

Wang et al (2018).

COVID-19 evidence methods: Systematic review and network meta-analysis of antibody therapies and blood products for COVID-19 used WHO COVID-19 database and multiple Chinese databases, applied risk-of-bias and GRADE assessments, and limited meta-analyses to interventions with adequate sample/events.

Definitions — Cell Therapy Terms

LAK cells — definition and brief description

DefinitionLymphocytes removed from the patient’s blood and grown in the presence of interleukin‑2 (IL‑2) to create lymphokine‑activated killer (LAK) cells for reinfusion

MechanismEx‑vivo activation/expansion with IL‑2 to boost anti‑tumor activity prior to reinfusion

Clinical noteEarly trials evaluated LAK plus high‑dose IL‑2; evidence did not show clear added benefit over IL‑2 alone in many settings

TILs — tumor-infiltrating lymphocytes definition

DefinitionTumor‑infiltrating lymphocytes (TILs) are lymphocytes isolated from a patient’s tumor tissue, expanded ex‑vivo (commonly with IL‑2) and reinfused to target tumor cells

RationaleTILs often show stronger tumor‑specific activity than peripheral blood lymphocytes because they are selected from the tumor microenvironment

LimitationsTIL‑based approaches require accessible tumor tissue and complex manufacturing, limiting applicability

TIL-based ACT — adoptive cell therapy using TILs definition and lymphodepletion context

DefinitionTIL‑based adoptive cell therapy (ACT) is infusion of T cells harvested from a patient’s fresh tumor, extensively expanded ex‑vivo and reinfused after a lymphodepleting preparative regimen

Preparative regimenTIL‑based ACT is typically administered following lymphodepleting chemotherapy (e.g., high‑dose cyclophosphamide/fludarabine) and often with IL‑2 support

Clinical statusTested mainly in phase I/II studies with notable response rates in metastatic melanoma but requires definitive phase III evidence for broad adoption

CIK / DC-CIK — cytokine-induced killer and dendritic cell priming definitions

CIK definitionCytokine‑induced killer (CIK) cells are peripheral blood–derived lymphocytes expanded ex‑vivo with cytokines to enhance anti‑tumor activity

DC‑CIKDC‑CIK refers to CIK cells combined with dendritic cell priming/education prior to infusion to potentially improve antigen presentation and efficacy

Clinical findingsMeta‑analyses and cohort studies report improved response metrics when DC/CIK are combined with chemotherapy in some cancers, but heterogeneity limits conclusions

NK / EBV-CTL — natural killer cells and EBV-specific cytotoxic T-lymphocytes definitions

NK cellsNatural killer (NK) cells are donor or autologous innate lymphocytes expanded/activated ex‑vivo and infused to mediate cytotoxicity against tumor cells

EBV‑CTLEBV‑specific cytotoxic T‑lymphocytes (EBV‑CTLs) are T cells expanded against Epstein‑Barr virus antigens for EBV‑associated malignancies

Clinical contextEBV‑CTLs have been administered after interim chemotherapy in EBV‑associated nasopharyngeal carcinoma trials, with occasional durable responses but overall limited PFS

EBV-CTL — EBV-stimulated cytotoxic T-lymphocyte product manufactured from patient blood

Product descriptionEBV‑CTL is an Epstein‑Barr virus‑stimulated cytotoxic T‑lymphocyte product manufactured from a patient’s blood to target EBV‑associated tumors

Use patternIn the cited NPC trial, EBV‑CTL manufacturing occurred while patients received interim chemotherapy; investigational therapy was given only after progression

Outcomes noteIn that study 21 patients treated yielded 1 complete response; median PFS was 2.2 months and median OS 16.7 months

Cellular therapy (unregulated/alternative) — definition of fresh cell/live cell/glandular therapies

DefinitionUnregulated cellular therapy (fresh cell/live cell/glandular therapy) involves injection or oral administration of processed animal organ, embryo, or fetal tissues purported to repair corresponding human organs

Regulatory/clinical stanceThese therapies lack scientific evidence of efficacy and carry risk of serious adverse reactions; professional bodies advise against their use

Common descriptorsAlso called embryonic cell therapy, xenotransplant therapy, organotherapy, or glandular therapy; products sourced from animals such as cows or sheep

CAR T cells — definition of autologous CAR T-cell therapies

DefinitionCAR‑T cells are autologous T cells genetically engineered ex‑vivo to express a chimeric antigen receptor targeting a tumor‑associated antigen (e.g., CD19)

Administration contextCAR‑T therapies are typically given after lymphodepleting chemotherapy and require specialized toxicity monitoring (e.g., for cytokine release syndrome)

Trial notesDose‑escalation trials define dosing levels and MTD; feasibility and reversible severe toxicities have been reported in pediatric/young‑adult CD19‑CAR T trials

Cell-based medicinal products (CBMPs) — regulatory cell therapies to modulate immune response

DefinitionCell‑based medicinal products (CBMPs) are regulatory cell therapies (e.g., regulatory T cells, dendritic cells, macrophages) intended to modulate immune responses

Clinical aimCBMPs have been investigated to reduce general immunosuppression in organ transplantation and to enable tailored immune regulation

Safety evidencePooled non‑randomized trials reported similar rejection rates and fewer infections in CBMP recipients compared with standard‑of‑care group over 60 weeks

Mesenchymal stromal cells (MSCs) — definition and investigated uses

DefinitionMesenchymal stromal cells (MSCs) are multipotent stromal cells investigated for regenerative and immunomodulatory effects across indications such as kidney disease, traumatic brain injury, and orthopedic repair

Preclinical evidenceMeta‑analysis of preclinical CKD studies found MSCs and bone‑marrow progenitors among the most effective cell types in animal models

Clinical statusMSCs remain under investigation with variable evidence across indications; route and cell origin influence outcomes in preclinical studies

TCR-transduced T cells — definition and note on peripheral blood detection/persistence

DefinitionTCR‑transduced T cells are T lymphocytes genetically modified to express a defined T‑cell receptor targeting tumor antigens

PersistenceClinical reports describe detection and persistence of transferred TCR‑transduced cells in peripheral blood for weeks to months and ex‑vivo antigen‑specific activity

Clinical implicationPersistence of engineered T cells does not always correlate with tumor regression, highlighting multiple mechanisms for activity and the role of preparative lymphodepletion

BMMNC therapy — bone marrow mononuclear cell infusion definition and STEMI context

DefinitionBone marrow mononuclear cell (BMMNC) therapy involves infusion of bone‑marrow‑derived mononuclear cells as adjunctive treatment after ST‑elevation myocardial infarction (STEMI)

Reported effectsMeta‑analysis of 24 trials (1,536 patients) reported reduced infarct size and improved myocardial perfusion but no consistent improvement in wall motion index or wall thickening

Clinical statusBMMNC intracoronary infusion was reported as safe in the analyzed trials, but further multicenter RCTs were recommended to validate efficacy

Azoospermia — definition and relevance to SCT systematic review

DefinitionAzoospermia is the absence of sperm in the ejaculate and a major cause of male infertility

Research contextSystematic review/meta‑analysis in animal models examined stem cell transplantation (SCT) approaches to induce spermatogenesis and repair damaged testis

Findings summarySCT improved expression of meiosis‑related genes and induced spermatogenesis in several animal models, with effects varying by transplant mode, injection site, stem cell type, and species

NDMM / RRMM — definitions and ASTCT recommendation context

NDMM definitionNewly diagnosed multiple myeloma (NDMM): initial presentation of multiple myeloma for which auto‑HCT consolidation remains a standard‑of‑care option

RRMM definitionRelapsed/refractory multiple myeloma (RRMM): disease that has relapsed after or is refractory to prior therapies; ASTCT recommended CAR‑T for RRMM after >=4 prior lines

ASTCT consensusRAND‑modified Delphi panel produced 20 consensus statements endorsing auto‑HCT in NDMM, recommending CAR‑T in RRMM after ≥4 prior lines, and advising frontline allo‑HCT/CAR‑T only in clinical trials

Policy Dates and Revision History

2002-08-20policy_effective

Policy became effective.

2023-09-13last_reviewLatest

Most recent clinical policy bulletin review completed.

2024-07-11scheduled_next_review

Next scheduled policy review date.

These background sections provide clinical context and evidence summaries but do not include explicit provider authorization actions or formal prior‑authorization requirements; they are informational summaries of the literature rather than implementation instructions.

Policy Summary

PayerAetna

PolicyAdoptive Immunotherapy and Cellular Therapy

Policy CodePolicy 0641

Change TypeNo material change

Effective DateAug 20, 2002

Next Review DateJul 11, 2024

Key ActionObtain and submit clinical trial evidence or peer-reviewed outcomes to support prior authorization requests for investigational adoptive or cellular therapies.

SourceLink

On This Page

Siemieniuk et al (2021).

Multiple myeloma ASTCT consensus: ASTCT expert panel produced consensus recommendations on timing and sequencing of autologous and allogeneic HCT and CAR-T in newly diagnosed and relapsed/refractory multiple myeloma, endorsing auto-HCT consolidation and recommending CAR-T for RRMM after ≥4 prior lines while advising against frontline allo-HCT and CAR-T outside trials.

Dhakal et al (2022).